Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Negar Aliabadi

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Plos One|July 1, 2025
Understanding the interaction of upper respiratory tract infection with respiratory syncytial virus and Streptococcus pneumoniae using a human challenge model: a multicenter, randomized controlled study protocolSanjita Brito-Mutunayagam, David O Hamilton, Elena Mitsi, et al.
American Heart Journal|May 31, 2026
A Pragmatic Randomized Trial to Evaluate the Vaccine Effectiveness of Bivalent RSV prefusion F Vaccine for Preventing RSV Hospitalizations in Adults (DAN-RSV): Trial Design UpdateMats C Højbjerg Lassen, Sine H Christensen, Niklas D Johansen, et al.
The Lancet. Global Health|June 16, 2019
Global impact of rotavirus vaccine introduction on rotavirus hospitalisations among children under 5 years of age, 2008-16: findings from the Global Rotavirus Surveillance NetworkNegar Aliabadi, Sébastien Antoni, Jason M Mwenda, et al.
Journal of the American College of Cardiology|August 30, 2025
Effect of RSV Vaccine on Heart Failure Hospitalizations: A Prespecified Analysis of the DAN-RSV TrialKristoffer Grundtvig Skaarup, Mats C Højbjerg Lassen, Niklas Dyrby Johansen, et al.
European Heart Journal|August 30, 2025
Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trialManan Pareek, Mats C Højbjerg Lassen, Niklas Dyrby Johansen, et al.
The New England Journal of Medicine|September 1, 2025
RSV Prefusion F Vaccine for Prevention of Hospitalization in Older AdultsMats C Højbjerg Lassen, Niklas Dyrby Johansen, Sine H Christensen, et al.
Diabetes Care|April 14, 2026
Bivalent RSV Prefusion F Protein-Based Vaccine Effectiveness in Individuals With and Without Diabetes: A Prespecified Analysis of the DAN-RSV TrialManan Pareek, Mats C Højbjerg Lassen, Niklas Dyrby Johansen, et al.
European Journal of Preventive Cardiology|June 18, 2026
Effect of RSV Vaccine in Older Adults with Atrial Fibrillation: A Prespecified Analysis of the DAN-RSV TrialCaroline Espersen, Mats C H Lassen, Niklas Dyrby Johansen, et al.
JAMA|August 30, 2025
Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV TrialMats C Højbjerg Lassen, Niklas Dyrby Johansen, Sine H Christensen, et al.
European Journal of Preventive Cardiology|April 30, 2026
Respiratory syncytial virus vaccination and risk of respiratory and cardiorespiratory hospitalization in adults with chronic kidney disease: a prespecified analysis of the DAN-RSV trialLisa Steen Duus, Mats C H Lassen, Niklas D Johansen, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Plos One|July 1, 2025
Understanding the interaction of upper respiratory tract infection with respiratory syncytial virus and Streptococcus pneumoniae using a human challenge model: a multicenter, randomized controlled study protocolSanjita Brito-Mutunayagam, David O Hamilton, Elena Mitsi, et al.
American Heart Journal|May 31, 2026
A Pragmatic Randomized Trial to Evaluate the Vaccine Effectiveness of Bivalent RSV prefusion F Vaccine for Preventing RSV Hospitalizations in Adults (DAN-RSV): Trial Design UpdateMats C Højbjerg Lassen, Sine H Christensen, Niklas D Johansen, et al.
The Lancet. Global Health|June 16, 2019
Global impact of rotavirus vaccine introduction on rotavirus hospitalisations among children under 5 years of age, 2008-16: findings from the Global Rotavirus Surveillance NetworkNegar Aliabadi, Sébastien Antoni, Jason M Mwenda, et al.
Journal of the American College of Cardiology|August 30, 2025
Effect of RSV Vaccine on Heart Failure Hospitalizations: A Prespecified Analysis of the DAN-RSV TrialKristoffer Grundtvig Skaarup, Mats C Højbjerg Lassen, Niklas Dyrby Johansen, et al.
European Heart Journal|August 30, 2025
Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trialManan Pareek, Mats C Højbjerg Lassen, Niklas Dyrby Johansen, et al.
The New England Journal of Medicine|September 1, 2025
RSV Prefusion F Vaccine for Prevention of Hospitalization in Older AdultsMats C Højbjerg Lassen, Niklas Dyrby Johansen, Sine H Christensen, et al.
Diabetes Care|April 14, 2026
Bivalent RSV Prefusion F Protein-Based Vaccine Effectiveness in Individuals With and Without Diabetes: A Prespecified Analysis of the DAN-RSV TrialManan Pareek, Mats C Højbjerg Lassen, Niklas Dyrby Johansen, et al.
European Journal of Preventive Cardiology|June 18, 2026
Effect of RSV Vaccine in Older Adults with Atrial Fibrillation: A Prespecified Analysis of the DAN-RSV TrialCaroline Espersen, Mats C H Lassen, Niklas Dyrby Johansen, et al.
JAMA|August 30, 2025
Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV TrialMats C Højbjerg Lassen, Niklas Dyrby Johansen, Sine H Christensen, et al.
European Journal of Preventive Cardiology|April 30, 2026
Respiratory syncytial virus vaccination and risk of respiratory and cardiorespiratory hospitalization in adults with chronic kidney disease: a prespecified analysis of the DAN-RSV trialLisa Steen Duus, Mats C H Lassen, Niklas D Johansen, et al.
Pageof 6